193 related articles for article (PubMed ID: 21629845)
1. Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.
Zhornitsky S; Stip E; Desfossés J; Pampoulova T; Rizkallah E; Rompré PP; Bentaleb LA; Lipp O; Chiasson JP; Gendron A; Potvin S
Front Psychiatry; 2011; 2():22. PubMed ID: 21629845
[TBL] [Abstract][Full Text] [Related]
2. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.
Zhornitsky S; Stip E; Pampoulova T; Rizkallah E; Lipp O; Bentaleb LA; Chiasson JP; Potvin S
Mov Disord; 2010 Oct; 25(13):2188-94. PubMed ID: 20669315
[TBL] [Abstract][Full Text] [Related]
3. Predictors of community functioning in schizophrenia and substance use disorder patients.
Zhornitsky S; Aubin G; Desfossés J; Rizkallah E; Pampoulova T; Lipp O; Chiasson JP; Stip E; Potvin S
Community Ment Health J; 2013 Jun; 49(3):317-22. PubMed ID: 22847727
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
6. Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients.
Zhornitsky S; Rizkallah E; Pampoulova T; Chiasson JP; Lipp O; Stip E; Potvin S
Psychiatry Res; 2012 Dec; 200(2-3):237-41. PubMed ID: 22980481
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
8. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.
Potvin S; Pampoulova T; Mancini-Marië A; Lipp O; Bouchard RH; Stip E
J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):796-8. PubMed ID: 16705205
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
10. Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study.
Potvin S; Mancini-Marie A; Fahim C; Mensour B; Stip E
Soc Neurosci; 2007; 2(2):106-16. PubMed ID: 18633810
[TBL] [Abstract][Full Text] [Related]
11. Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study.
Lombardozzi G; Trovini G; Amici E; Kotzalidis GD; Perrini F; Giovanetti V; Di Giovanni A; De Filippis S
Front Psychiatry; 2023; 14():1321233. PubMed ID: 38111619
[TBL] [Abstract][Full Text] [Related]
12. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
13. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.
Potvin S; Kouassi E; Lipp O; Bouchard RH; Roy MA; Demers MF; Gendron A; Astarita G; Piomelli D; Stip E
J Psychopharmacol; 2008 May; 22(3):262-9. PubMed ID: 18308802
[TBL] [Abstract][Full Text] [Related]
14. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use.
Margolese HC; Carlos Negrete J; Tempier R; Gill K
Schizophr Res; 2006 Mar; 83(1):65-75. PubMed ID: 16460917
[TBL] [Abstract][Full Text] [Related]
15. Impact of substance use disorder on presentation and short-term course of schizophrenia.
Chakraborty R; Chatterjee A; Chaudhury S
Psychiatry J; 2014; 2014():280243. PubMed ID: 24839596
[TBL] [Abstract][Full Text] [Related]
16. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
Glick ID; Marder SR
J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
[TBL] [Abstract][Full Text] [Related]
17. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.
Wobrock T; Falkai P; Schneider-Axmann T; Hasan A; Galderisi S; Davidson M; Kahn RS; Derks EM; Boter H; Rybakowski JK; Libiger J; Dollfus S; López-Ibor JJ; Peuskens J; Hranov LG; Gaebel W; Fleischhacker WW;
Schizophr Res; 2013 Jun; 147(1):132-139. PubMed ID: 23537477
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
19. Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia.
Desfossés J; Stip E; Bentaleb LA; Lipp O; Chiasson JP; Furtos A; Venne K; Kouassi E; Potvin S
Front Psychiatry; 2012; 3():85. PubMed ID: 23055987
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
